| Autor: |
Amy Berrington de González, DPhil, Todd M. Gibson, PhD, Choonsik Lee, PhD, Paul S. Albert, PhD, Keith T. Griffin, MS, Cari Meinhold Kitahara, PhD, Danping Liu, PhD, Matthew M. Mille, PhD, Jungwook Shin, PhD, Benjamin V.M. Bajaj, PhD, Tristin E. Flood, MS, Sara L. Gallotto, MS, Harald Paganetti, PhD, Safia K. Ahmed, MD, Bree R. Eaton, MD, Daniel J. Indelicato, MD, Sarah A. Milgrom, MD, Joshua D. Palmer, MD, Sujith Baliga, MD, Matthew M. Poppe, MD, Derek S. Tsang, MD, Kenneth Wong, MD, Torunn I. Yock, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101273- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2452-1094 |
| DOI: |
10.1016/j.adro.2023.101273 |
| Popis: |
Purpose: The physical properties of protons lower doses to surrounding normal tissues compared with photons, potentially reducing acute and long-term adverse effects, including subsequent cancers. The magnitude of benefit is uncertain, however, and currently based largely on modeling studies. Despite the paucity of directly comparative data, the number of proton centers and patients are expanding exponentially. Direct studies of the potential risks and benefits are needed in children, who have the highest risk of radiation-related subsequent cancers. The Pediatric Proton and Photon Therapy Comparison Cohort aims to meet this need. Methods and Materials: We are developing a record-linkage cohort of 10,000 proton and 10,000 photon therapy patients treated from 2007 to 2022 in the United States and Canada for pediatric central nervous system tumors, sarcomas, Hodgkin lymphoma, or neuroblastoma, the pediatric tumors most frequently treated with protons. Exposure assessment will be based on state-of-the-art dosimetry facilitated by collection of electronic radiation records for all eligible patients. Subsequent cancers and mortality will be ascertained by linkage to state and provincial cancer registries in the United States and Canada, respectively. The primary analysis will examine subsequent cancer risk after proton therapy compared with photon therapy, adjusting for potential confounders and accounting for competing risks. Results: For the primary aim comparing overall subsequent cancer rates between proton and photon therapy, we estimated that with 10,000 patients in each treatment group there would be 80% power to detect a relative risk of 0.8 assuming a cumulative incidence of subsequent cancers of 2.5% by 15 years after diagnosis. To date, 9 institutions have joined the cohort and initiated data collection; additional centers will be added in the coming year(s). Conclusions: Our findings will affect clinical practice for pediatric patients with cancer by providing the first large-scale systematic comparison of the risk of subsequent cancers from proton compared with photon therapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
